The invention relates to the field of medicine, and more particularly to emergency medical assistance. A respiratory intervention is performed on a patient with an artificial gas-air mixture having an increased content of argon of at least 30 vol %, enabling this artificial gas-air mixture to be effective continuously throughout the procedure. Furthermore, the respiratory gaseous medium has an increased content of oxygen with xenon being added and has the following composition: 1-10 vol % of xenon; 30-35 vol % of argon; 60-65 vol % of oxygen. The intervention on the patient with the artificial gas-air mixture of the composition mentioned is performed for 20-40 minutes or more, until specialized medical assistance is given. The method makes it possible to increase the effectiveness, safety and rapidity of relieving acute cerebral and cardiac ischemia, and to reduce the risk of developing an acute cerebral stroke or myocardial infarction.

The present invention relates to a mixed-charge nanoparticle for inducing selective death of cancer cells and a use thereof. The mixed-charge nanoparticle of the present invention is localized and crystallized specifically in cancer cell lysosomes through a pH-dependent aggregation behavior due to the balance between positively charged ligands and negatively charged ligands on the surface thereof and can induce lysosomal membrane permeabilization (LMP) and lysosomal cell death mediated thereby, like cationic amphiphilic drugs (CADs) Exhibiting a cancer cell-specific death effect, the nanoparticles of the present invention can surmount the limited medical use of conventional cationic nanoparticles due to the non-specific cytotoxicity thereof. Particularly, the nanoparticles of the present invention do not exhibit toxicity to the human body and normal cells, thus finding useful applications in medical and medicinal uses such as for prevention and treatment of solid cancer, blood cancer, and tumors.

The present invention relates to a mixed-charge nanoparticle for inducing selective death of cancer cells and a use thereof. The mixed-charge nanoparticle of the present invention is localized and crystallized specifically in cancer cell lysosomes through a pH-dependent aggregation behavior due to the balance between positively charged ligands and negatively charged ligands on the surface thereof and can induce lysosomal membrane permeabilization (LMP) and lysosomal cell death mediated thereby, like cationic amphiphilic drugs (CADs) Exhibiting a cancer cell-specific death effect, the nanoparticles of the present invention can surmount the limited medical use of conventional cationic nanoparticles due to the non-specific cytotoxicity thereof. Particularly, the nanoparticles of the present invention do not exhibit toxicity to the human body and normal cells, thus finding useful applications in medical and medicinal uses such as for prevention and treatment of solid cancer, blood cancer, and tumors.

A method for producing a carbon dioxide-containing hydrogel article including (1) to (3). (1) Preparing an article including a hydrogel that contains a water-soluble polymer, a cross-linking agent for the water-soluble polymer, and water, wherein a loss tangent of the hydrogel at 1 Hz in dynamic viscoelasticity measurement is 0.46 or greater. (2) Adjusting a composition of an ambient atmosphere of the article including the hydrogel such that a carbon dioxide gas concentration in the ambient atmosphere becomes 10 vol% or greater, and sealing the article including the hydrogel inside a package. (3) Making cross-linking of the hydrogel proceed until the loss tangent, at 1 Hz in dynamic viscoelasticity measurement, of the hydrogel in the article including the hydrogel becomes less than 0.46, and thereby obtaining a carbon dioxide-containing hydrogel article sealed inside the package.

A method for producing a carbon dioxide-containing hydrogel article including (1) to (3). (1) Preparing an article including a hydrogel that contains a water-soluble polymer, a cross-linking agent for the water-soluble polymer, and water, wherein a loss tangent of the hydrogel at 1 Hz in dynamic viscoelasticity measurement is 0.46 or greater. (2) Adjusting a composition of an ambient atmosphere of the article including the hydrogel such that a carbon dioxide gas concentration in the ambient atmosphere becomes 10 vol% or greater, and sealing the article including the hydrogel inside a package. (3) Making cross-linking of the hydrogel proceed until the loss tangent, at 1 Hz in dynamic viscoelasticity measurement, of the hydrogel in the article including the hydrogel becomes less than 0.46, and thereby obtaining a carbon dioxide-containing hydrogel article sealed inside the package.

The present disclosure provides a nutritional formula comprising alpha-lactalbumin enriched whey protein concentrate; beta-casein enriched milk protein; mildly hydrolyzed milk protein; osteopontin; lactoferrin; oleic acid-palmitic acid-oleic acid triglyceride, wherein palmitic acid is at the SN-2 position of the glycerol backbone of the triglyceride; lactose, wherein the lactose is reduced lactose; lutein; docosahexanoic acid; arachidonic acid; galactooligosaccharides; and polydextrose. The provided nutritional formulas may be useful in providing nutrition and/or promoting postnatal development of a subject (e.g., promoting postnatal development of an infant's gastrointestinal functions, nutrient absorption, immune system development, etc.). Also provided are powder forms, reconstituted formulas, kits, methods, and uses that include or involve a nutritional formula described herein.

The present disclosure provides a nutritional formula comprising alpha-lactalbumin enriched whey protein concentrate; beta-casein enriched milk protein; mildly hydrolyzed milk protein; osteopontin; lactoferrin; oleic acid-palmitic acid-oleic acid triglyceride, wherein palmitic acid is at the SN-2 position of the glycerol backbone of the triglyceride; lactose, wherein the lactose is reduced lactose; lutein; docosahexanoic acid; arachidonic acid; galactooligosaccharides; and polydextrose. The provided nutritional formulas may be useful in providing nutrition and/or promoting postnatal development of a subject (e.g., promoting postnatal development of an infant's gastrointestinal functions, nutrient absorption, immune system development, etc.). Also provided are powder forms, reconstituted formulas, kits, methods, and uses that include or involve a nutritional formula described herein.

The present disclosure is directed to methods of treating a steatosis-associated disorder by administering a therapeutic agent selected from a lysosomal enzyme, an autophagy-inducing agent, or a combination thereof. Steatosis-associated disorders discussed herein include GSD Ia, GSD Ib, GSD Ic, NAFLD, and NASH. Other embodiments are directed to methods of reversing steatosis, modulating autophagy, inducing autophagy, and reversing glycogen storage.

The present disclosure is directed to methods of treating a steatosis-associated disorder by administering a therapeutic agent selected from a lysosomal enzyme, an autophagy-inducing agent, or a combination thereof. Steatosis-associated disorders discussed herein include GSD Ia, GSD Ib, GSD Ic, NAFLD, and NASH. Other embodiments are directed to methods of reversing steatosis, modulating autophagy, inducing autophagy, and reversing glycogen storage.

The present disclosure is directed to a method of treating a neuropsychiatric disorder. This method involves selecting a subject having the neuropsychiatric disorder and administering to the selected subject a preparation of glial progenitor cells at a dosage effective to treat the neuropsychiatric disorder in the subject. Another aspect of the disclosure is directed to a method of treating a neuropsychiatric disorder that includes selecting a subject having the neuropsychiatric disorder and administering, to the selected subject, a potassium (K.sup.+) channel activator at a dosage effective to restore normal brain interstitial glial K.sup.+ levels in the selected subject and treat the neuropsychiatric disorder is also disclosed.